Vaxcell-Bio Therapeutics Co. Ltd
Vaxcell-Bio Therapeutics Co., Ltd. develops and sells cancer immune cell therapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea.
Market Cap & Net Worth: Vaxcell-Bio Therapeutics Co. Ltd (323990)
Vaxcell-Bio Therapeutics Co. Ltd (KQ:323990) has a market capitalization of $131.21 Million (₩192.11 Billion) as of March 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #18102 globally and #650 in its home market, demonstrating a 5.87% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vaxcell-Bio Therapeutics Co. Ltd's stock price ₩8290.00 by its total outstanding shares 23173887 (23.17 Million).
Vaxcell-Bio Therapeutics Co. Ltd Market Cap History: 2020 to 2026
Vaxcell-Bio Therapeutics Co. Ltd's market capitalization history from 2020 to 2026. Data shows growth from $2.00 Billion to $131.21 Million (0.59% CAGR).
Index Memberships
Vaxcell-Bio Therapeutics Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.85 Billion | 0.06% | #266 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.85 Billion | 0.06% | #266 of 1384 |
Weight: Vaxcell-Bio Therapeutics Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Vaxcell-Bio Therapeutics Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vaxcell-Bio Therapeutics Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.09x
Vaxcell-Bio Therapeutics Co. Ltd's market cap is 0.09 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $355.32 Million | $13.72 Million | -$10.27 Billion | 25.89x | N/A |
| 2024 | $165.08 Million | $1.90 Billion | -$10.62 Billion | 0.09x | N/A |
Competitor Companies of 323990 by Market Capitalization
Companies near Vaxcell-Bio Therapeutics Co. Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Vaxcell-Bio Therapeutics Co. Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Vaxcell-Bio Therapeutics Co. Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Vaxcell-Bio Therapeutics Co. Ltd's market cap moved from $2.00 Billion to $ 131.21 Million, with a yearly change of 0.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩131.21 Million | -17.02% |
| 2025 | ₩158.11 Million | -4.22% |
| 2024 | ₩165.08 Million | -53.54% |
| 2023 | ₩355.32 Million | -12.75% |
| 2022 | ₩407.26 Million | -21.31% |
| 2021 | ₩517.57 Million | -74.06% |
| 2020 | ₩2.00 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Vaxcell-Bio Therapeutics Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $131.21 Million USD |
| MoneyControl | $131.21 Million USD |
| MarketWatch | $131.21 Million USD |
| marketcap.company | $131.21 Million USD |
| Reuters | $131.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.